CD8+ T Cell Amplification Using TLR Agonists and Cytokines
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to efficiently amplify PD-1+CD8+ T cells and other functional CD8+ T cell subpopulations in vitro, which are crucial for anti-tumor and anti-infection immunity, due to limited amplification efficiency and reduced cytokine secretion capacity.
Innovation Solution
The use of Toll-like receptor (TLR) agonists such as TLR1/2, TLR2/6, and TLR5 agonists in combination with anti-human CD3 and CD28 antibodies, along with cytokines like IL-2, IL-7, and IL-15, enhances the in-vitro amplification and activation of CD8+ T cells and their functional subpopulations, including PD-1+CD8+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional culture methods using anti-CD3 antibody, IL-2 and IL-7 are used to amplify CD8+ T cells, then cell proliferation is achieved, but the amplification efficiency is limited and functional subpopulations such as PD-1+CD8+ T cells are difficult to amplify
Solution Approach 1:
The patent changes the cytokine parameters from conventional IL-2/IL-7 to IL-15/IL-7 combination, and adds TLR agonists to the culture system. This parameter change enables significant amplification of functional CD8+ T cell subpopulations including PD-1+CD8+ T cells, overcoming the limitation of conventional methods that fail to amplify these functional subpopulations effectively
Solution Approach 2:
The patent creates a composite culture system combining anti-CD3 antibody, anti-CD28 antibody, multiple cytokines (IL-15, IL-7), and TLR agonists. This composite approach synergistically enhances both the quantity and quality of amplified CD8+ T cells, achieving high amplification efficiency while maintaining functional subpopulations
2Reliability
If PD-1 blocking antibodies are used to restore function of depleted T cells, then biological function is partially restored, but the phenotype cannot be reversed leading to tumor recurrence
Solution Approach 1:
The patent applies TLR agonists and optimized cytokine combinations (IL-15/IL-7) in advance during in-vitro amplification to prevent phenotype degradation and actively promote functional differentiation. This preliminary action ensures that amplified cells maintain high functionality and appropriate phenotype, avoiding the need for post-amplification PD-1 blocking and achieving complete functional restoration
Solution Approach 2:
The patent uses TLR agonists as intermediary substances that bridge the gap between conventional amplification methods and functional restoration. These TLR agonists act as mediators that not only enhance proliferation but also drive functional differentiation and phenotype maintenance, achieving both function restoration and phenotype reversal simultaneously
Data Source
AI summary
Disclosed is a method for rapidly amplifying CD8+T cells and functional cell subpopulations thereof in vitro. A TLR1/2 agonist, a TLR2/6 agonist and a TLR5 agonist or a combination of above agonists is added to a conventional culture system for in-vitro amplification of CD8+T cells. Recombinant cytokines IL-2, IL-7 and IL-15 as well as magnetic beads coated with an anti-human CD3 antibody and an anti-human CD28 antibody can be further added to the culture system for continuous co-stimulation.